Eagle Health Investments LP Buys 541,039 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Eagle Health Investments LP boosted its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 35.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 2,060,427 shares of the company’s stock after buying an additional 541,039 shares during the quarter. Compass Pathways makes up 2.0% of Eagle Health Investments LP’s holdings, making the stock its 20th largest holding. Eagle Health Investments LP’s holdings in Compass Pathways were worth $11,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways in the fourth quarter valued at about $38,000. Parallel Advisors LLC increased its stake in Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the period. Advisory Services Network LLC acquired a new position in Compass Pathways in the 3rd quarter valued at approximately $41,000. North Star Investment Management Corp. raised its holdings in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Compass Pathways in the 4th quarter worth approximately $47,000. 46.19% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CMPS shares. UBS Group set a $18.00 price objective on Compass Pathways in a report on Thursday, May 7th. Royal Bank Of Canada upped their target price on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Stifel Nicolaus boosted their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Finally, Morgan Stanley restated an “overweight” rating and issued a $17.00 price objective on shares of Compass Pathways in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways has an average rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Price Performance

Compass Pathways stock opened at $11.27 on Tuesday. The business has a 50 day simple moving average of $12.52 and a 200 day simple moving average of $9.06. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The company has a market capitalization of $1.52 billion, a PE ratio of -3.58 and a beta of 2.47. Compass Pathways PLC Sponsored ADR has a one year low of $3.92 and a one year high of $15.40.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. On average, sell-side analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.